Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials

Chad A. Bousman; Katarina Arandjelovic; Serafino G. Mancuso; Harris A. Eyre; Boadie W. Dunlop

doi:10.2217/pgs-2018-0142

Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials

Chad A. Bousman, Katarina Arandjelovic, Serafino G. Mancuso, Harris A. Eyre, Boadie W. Dunlop

Research output: Contribution to journal › Article › peer-review

132 Scopus citations

Abstract

Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD). Patients & methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. Results & conclusion: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17-2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.

Original language	English (US)
Pages (from-to)	37-47
Number of pages	11
Journal	Pharmacogenomics
Volume	20
Issue number	1
DOIs	https://doi.org/10.2217/pgs-2018-0142
State	Published - Jan 2019

Keywords

Antidepressants
Clinical decision support
Depression
Genetic
Pharmacogenetics

ASJC Scopus subject areas

Molecular Medicine
Genetics
Pharmacology

Access to Document

10.2217/pgs-2018-0142

Cite this

@article{2d04128a9b3d434c974ccdb12f547076,

title = "Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials",

abstract = "Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD). Patients & methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. Results & conclusion: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17-2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.",

keywords = "Antidepressants, Clinical decision support, Depression, Genetic, Pharmacogenetics",

author = "Bousman, {Chad A.} and Katarina Arandjelovic and Mancuso, {Serafino G.} and Eyre, {Harris A.} and Dunlop, {Boadie W.}",

note = "Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",

year = "2019",

month = jan,

doi = "10.2217/pgs-2018-0142",

language = "English (US)",

volume = "20",

pages = "37--47",

journal = "Pharmacogenomics",

issn = "1462-2416",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - Pharmacogenetic tests and depressive symptom remission

T2 - A meta-analysis of randomized controlled trials

AU - Bousman, Chad A.

AU - Arandjelovic, Katarina

AU - Mancuso, Serafino G.

AU - Eyre, Harris A.

AU - Dunlop, Boadie W.

PY - 2019/1

Y1 - 2019/1

N2 - Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD). Patients & methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. Results & conclusion: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17-2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.

AB - Aim: To conducted a systematic review and meta-analysis of prospective, randomized controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools (DSTs) relevant to depressive symptom remission in major depressive disorder (MDD). Patients & methods: Random-effects meta-analysis was performed on RCTs that examined the effect of DSTs on remission rates in MDD. RCT quality was assessed using the Cochrane Collaboration Criteria. Results & conclusion: A total of 1737 eligible subjects from five RCTs were examined. Individuals receiving pharmacogenetic-guided DST therapy (n = 887) were 1.71 (95% CI: 1.17-2.48; p = 0.005) times more likely to achieve symptom remission relative to individuals who received treatment as usual (n = 850). Pharmacogenetic-guided DSTs might improve symptom remission among those with MDD.

KW - Antidepressants

KW - Clinical decision support

KW - Depression

KW - Genetic

KW - Pharmacogenetics

UR - http://www.scopus.com/inward/record.url?scp=85058346228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058346228&partnerID=8YFLogxK

U2 - 10.2217/pgs-2018-0142

DO - 10.2217/pgs-2018-0142

M3 - Article

C2 - 30520364

AN - SCOPUS:85058346228

SN - 1462-2416

VL - 20

SP - 37

EP - 47

JO - Pharmacogenomics

JF - Pharmacogenomics

IS - 1

ER -

Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this